222 related articles for article (PubMed ID: 29803106)
1. Glutathione-depletion mesoporous organosilica nanoparticles as a self-adjuvant and Co-delivery platform for enhanced cancer immunotherapy.
Lu Y; Yang Y; Gu Z; Zhang J; Song H; Xiang G; Yu C
Biomaterials; 2018 Aug; 175():82-92. PubMed ID: 29803106
[TBL] [Abstract][Full Text] [Related]
2. Hollow Mesoporous Silica Nanoparticles with Extra-Large Mesopores for Enhanced Cancer Vaccine.
Lee JY; Kim MK; Nguyen TL; Kim J
ACS Appl Mater Interfaces; 2020 Aug; 12(31):34658-34666. PubMed ID: 32662625
[TBL] [Abstract][Full Text] [Related]
3. Mesoporous Silica as a Versatile Platform for Cancer Immunotherapy.
Nguyen TL; Choi Y; Kim J
Adv Mater; 2019 Aug; 31(34):e1803953. PubMed ID: 30417454
[TBL] [Abstract][Full Text] [Related]
4. Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis.
Xu Z; Ramishetti S; Tseng YC; Guo S; Wang Y; Huang L
J Control Release; 2013 Nov; 172(1):259-265. PubMed ID: 24004885
[TBL] [Abstract][Full Text] [Related]
5. Induction of a balanced Th1/Th2 immune responses by co-delivery of PLGA/ovalbumin nanospheres and CpG ODNs/PEI-SWCNT nanoparticles as TLR9 agonist in BALB/c mice.
Ebrahimian M; Hashemi M; Maleki M; Abnous K; Hashemitabar G; Ramezani M; Haghparast A
Int J Pharm; 2016 Dec; 515(1-2):708-720. PubMed ID: 27989827
[TBL] [Abstract][Full Text] [Related]
6. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
[TBL] [Abstract][Full Text] [Related]
7. Microdosed Lipid-Coated (67)Ga-Magnetite Enhances Antigen-Specific Immunity by Image Tracked Delivery of Antigen and CpG to Lymph Nodes.
Ruiz-de-Angulo A; Zabaleta A; Gómez-Vallejo V; Llop J; Mareque-Rivas JC
ACS Nano; 2016 Jan; 10(1):1602-18. PubMed ID: 26678549
[TBL] [Abstract][Full Text] [Related]
8. Rational design of Polymeric Hybrid Micelles to Overcome Lymphatic and Intracellular Delivery Barriers in Cancer Immunotherapy.
Li H; Li Y; Wang X; Hou Y; Hong X; Gong T; Zhang Z; Sun X
Theranostics; 2017; 7(18):4383-4398. PubMed ID: 29158834
[TBL] [Abstract][Full Text] [Related]
9. Polyethylenimine Hybrid Thin-Shell Hollow Mesoporous Silica Nanoparticles as Vaccine Self-Adjuvants for Cancer Immunotherapy.
Liu Q; Zhou Y; Li M; Zhao L; Ren J; Li D; Tan Z; Wang K; Li H; Hussain M; Zhang L; Shen G; Zhu J; Tao J
ACS Appl Mater Interfaces; 2019 Dec; 11(51):47798-47809. PubMed ID: 31773941
[TBL] [Abstract][Full Text] [Related]
10. In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy.
Han HD; Byeon Y; Jang JH; Jeon HN; Kim GH; Kim MG; Pack CG; Kang TH; Jung ID; Lim YT; Lee YJ; Lee JW; Shin BC; Ahn HJ; Sood AK; Park YM
Sci Rep; 2016 Dec; 6():38348. PubMed ID: 27910914
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma.
Zhu M; Ding X; Zhao R; Liu X; Shen H; Cai C; Ferrari M; Wang HY; Wang RF
J Control Release; 2018 Feb; 272():72-82. PubMed ID: 29325699
[TBL] [Abstract][Full Text] [Related]
12. In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines.
Beaudette TT; Bachelder EM; Cohen JA; Obermeyer AC; Broaders KE; Fréchet JM; Kang ES; Mende I; Tseng WW; Davidson MG; Engleman EG
Mol Pharm; 2009; 6(4):1160-9. PubMed ID: 19415922
[TBL] [Abstract][Full Text] [Related]
13. Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response.
Liang R; Xie J; Li J; Wang K; Liu L; Gao Y; Hussain M; Shen G; Zhu J; Tao J
Biomaterials; 2017 Dec; 149():41-50. PubMed ID: 28992509
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy.
Han HD; Byeon Y; Kang TH; Jung ID; Lee JW; Shin BC; Lee YJ; Sood AK; Park YM
Int J Nanomedicine; 2016; 11():5729-5742. PubMed ID: 27843314
[TBL] [Abstract][Full Text] [Related]
15. CpG oligodeoxynucleotides augment antitumor efficacy of folate receptor α based DNA vaccine.
Qiu Z; Xing L; Zhang X; Qiang X; Xu Y; Zhang M; Zhou Z; Zhang J; Zhang F; Wang M
Oncol Rep; 2017 Jun; 37(6):3441-3448. PubMed ID: 28498413
[TBL] [Abstract][Full Text] [Related]
16. Metal-Phenolic Network-Encapsulated Nanovaccine with pH and Reduction Dual Responsiveness for Enhanced Cancer Immunotherapy.
Zhou X; Su Q; Zhao H; Cao X; Yang Y; Xue W
Mol Pharm; 2020 Dec; 17(12):4603-4615. PubMed ID: 33175556
[TBL] [Abstract][Full Text] [Related]
17. Cascade Cytosol Delivery of Dual-Sensitive Micelle-Tailored Vaccine for Enhancing Cancer Immunotherapy.
Jiang D; Mu W; Pang X; Liu Y; Zhang N; Song Y; Garg S
ACS Appl Mater Interfaces; 2018 Nov; 10(44):37797-37811. PubMed ID: 30360105
[TBL] [Abstract][Full Text] [Related]
18. Biomimetic virus-like mesoporous silica nanoparticles improved cellular internalization for co-delivery of antigen and agonist to enhance Tumor immunotherapy.
Gao Y; Zhang Y; Xia H; Ren Y; Zhang H; Huang S; Li M; Wang Y; Li H; Liu H
Drug Deliv; 2023 Dec; 30(1):2183814. PubMed ID: 36843529
[TBL] [Abstract][Full Text] [Related]
19. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine.
Shi GN; Zhang CN; Xu R; Niu JF; Song HJ; Zhang XY; Wang WW; Wang YM; Li C; Wei XQ; Kong DL
Biomaterials; 2017 Jan; 113():191-202. PubMed ID: 27816821
[TBL] [Abstract][Full Text] [Related]
20. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes.
Zaks K; Jordan M; Guth A; Sellins K; Kedl R; Izzo A; Bosio C; Dow S
J Immunol; 2006 Jun; 176(12):7335-45. PubMed ID: 16751377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
